Role of adenosine receptors in resveratrol-induced intraocular pressure lowering in rats with steroid-induced ocular hypertension

Clinical and Experimental Ophthalmology

Volumn 43, Issue 1, 2015, Pages 54-66

  Razali, Norhafiza ^a   Agarwal, Renu ^a   Agarwal, Puneet ^a   Kumar, Sunil ^b   Tripathy, Minaketan ^c   Vasudevan, Sushil ^a   Crowston, Jonathan G ^d   Ismail, Nafeeza M ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c ICAR NATIONAL BUREAU OF AGRICULTURALLY IMPORTANT MICROORGANISMS   (India)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adenosine receptors; Docking simulation; Intraocular pressure; Resveratrol; Topical

Indexed keywords

ADENOSINE RECEPTOR; RESVERATROL; STEROID; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; DEXAMETHASONE; EYE DROPS; GLUCOCORTICOID; STILBENE DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG RESPONSE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; OCULOHYPOTENSIVE EFFECT; PROTEIN INTERACTION; RAT; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; GLUCOCORTICOIDS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; STILBENES; TONOMETRY, OCULAR;

EID: 84921441380     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12375     Document Type: Article

References (48)

1. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17: 163-167.
2. Ang M, Ti SE, Loh R etal. Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis. Clin Ophthalmol 2012; 6: 1253-1258.
3. Smithen LM, Ober MD, Maranan L etal. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138: 740-743.
4. Jonas JB, Kreissig I, Degenrigh RF. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-27.
5. Jonas JB, Degenrigh RF, Kreissig I etal. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598.
6. Avila MY, Stone RA, Civan MM. A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol 2001; 134: 241-245.
7. Crosson CE. Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. Invest Ophthalmol Vis Sci 2001; 42: 1837-1840.
8. Konno T, Murakami A, Uchibori T etal. Involvement of adenosine A2a receptor in intraocular pressure decrease induced by 2-(1-octyn-1-yl)adenosine or 2-(6-cyano-1-hexyn-1-yl)adenosine. J Pharmacol Sci 2005; 97: 501-509.
9. Wang Z, Do CW, Avila MY etal. Neucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. Exp Eye Res 2010; 90: 146-154.
10. Anisimova NY, Kiselevsky MV, Sosnov AV etal. Trans-, cis-, and dihydro-resveratrol: a comparative study. Chem Cent J 2011; 5: 88-93.
11. Zhao T, Xi L, Chelliah J etal. Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: evidence from gene-knockout mice. Circulation 2000; 102: 902-907.
12. Gupta YK, Chaudhary G, Srivastava AK. Protective effect of resveratrol against pentylenetetrazole-induced seizures and its modulation by an adenosinergic system. Pharmacology 2002; 65: 170-174.
13. Das S, Cordis GA, Maulik N etal. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol 2005; 288: H328-335.
14. Agarwal R, Gupta SK, Agrawal SS, Srivastava S, Saxena R. Oculohypotensive effects of foeniculum vulgare in experimental models of glaucoma. Indian J Physiol Pharmacol 2008; 52: 77-83.
15. Altschul SF, Gish W, Miller W etal. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
16. Berman M, Westbrook J, Feng Z etal. The protein data bank. Nucleic Acids Res 2000; 28: 235-242.
17. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
18. Laskoswki RA, MacArthur MW, Moss DS etal. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26: 283-291.
19. Eisenberg D, Luthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 1997; 277: 396-404.
20. Heing M, Frishman D. STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins. Nucleic Acids Res 2004; 32: W500-502.
21. Jones G, Willett P, Glen RC etal. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-748.
22. Wang R, Lai L, Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 2002; 16: 11-26.
23. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interaction. Protein Eng 1995; 8: 127.
24. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res 2009; 88: 752-759.
25. Crosson CE. Ocular hypotensive activity of the adenosine agonist (R)-phenylisopropyladenosine in rabbits. Curr Eye Res 1992; 11: 453-458.
26. Avila MY, Stone RA, Civan MM. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest Ophthalmol Vis Sci 2002; 43: 3021-3026.
27. Polska E, Ehrlich P, Luksch A etal. Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans. Invest Ophthalmol Vis Sci 2003; 44: 3110-3114.
28. Konno T, Ohnuma SY, Uemoto K etal. Effects of 2-alkynyladenosine derivatives on intraocular pressure in rabbits. Eur J Pharmacol 2004; 486: 307-316.
29. Schlötzer-Schrehardt U, Zenkel M, Decking U etal. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 2005; 46: 2023-2034.
30. Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther 2007; 320: 258-265.
31. Li A, Banerjee J, Leung CT etal. Mechanisms of ATP release, the enabling step in purinergic dynamics. Cell Physiol Biochem 2011; 28: 1135-1144.
32. Li A, Leung CT, Peterson-Yantorno K etal. Mechanisms of ATP release by human trabecular meshwork cells, the enabling step in purinergic regulation of aqueous humor outflow. J Cell Physiol 2012; 227: 172-182.
33. Wax M, Sanghavi DM, Lee CH etal. Purinergic receptors in ocular ciliary epithelial cells. Exp Eye Res 1993; 57: 89-95.
34. Kvanta A, Seregard S, Sejersen S etal. Localization of adenosine receptor messenger RNAs in the rat eye. Exp Eye Res 1997; 65: 595-602.
35. Agarwal R, Agarwal P. Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways. Expert Opin Ther Targets 2014; 18: 527-539.
36. Mitchell CH, Peterson-Yantorno K, Carre DA etal. A3 adenosine receptors regulate Cl- channels of nonpigmented ciliary epithelial cells. Am J Physiol 1999; 276: C659-666.
37. Jacobson KA, Park KS, Jiang JL etal. Pharmacological characterization of novel A3 adenosine receptor- selective antagonists. Neuropharmacology 1997; 36: 1157-1165.
38. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-787.
39. Ferkany JW, Valentine HL, Stone GA etal. Adenosine A1 receptors in mammalian brain: species differences in their interactions with agonist and antagonist. Drug Dev Res 1986; 9: 85-93.
40. Crosson CE, Gray T. Modulation of intraocular pressure by adenosine agonists. J Ocul Pharmacol 1994; 10: 379-383.
41. Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther 1995; 273: 320-326.
42. Tian B, Gabelt BT, Crosson CE etal. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res 1997; 64: 979-989.
43. Karl MO, Fleischhauer JC, Stamer WD etal. Differential P1-purinergic modulation of human Schlemm's canal inner-wall cells. Am J Physiol 2001; 288: C784-794.
44. Fredholm BB, Irenius E, Kull B etal. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001; 61: 443-448.
45. Carre DA, Mitchell CH, Peterson-Yantorno K etal. Adenosine stimulates Cl- channels of nonpigmented ciliary epithelial cells. Am J Physiol 1997; 273: C1354-1361.
46. Carre DA, Mitchell CH, Peterson-Yantorno K etal. Similarity of A3-adenosine and swelling-activated Cl- channels in nonpigmented ciliary epithelial cells. Am J Physiol Cell Physiol 2000; 279: C440-451.
47. Civan MM. The fall and rise of active chloride transport: implications for regulation of intraocular pressure. J Exp Zool A Comp Exp Biol 2003; 300: 5-13.
48. Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. Exp Eye Res 2004; 78: 625-631.